Advertisement

Topics

Latest "Sitka Limited" News Stories

00:20 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "Sitka Limited" found in our extensive news archives from over 250 global news sources.

More Information about Sitka Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sitka Limited for you to read. Along with our medical data and news we also list Sitka Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sitka Limited Companies for you to search.

Showing "Sitka Limited" News Articles 1–25 of 300

Wednesday 12th December 2018

Avacta appoints Dr Jose Saro as Chief Medical Officer

Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s ...


Tuesday 11th December 2018

IONTAS founder and phage display pioneer attends Nobel Prize Award Ceremony.

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribut...

Monday 10th December 2018

Quotient Limited Announces Receipt of the ISO 13485:2016 Certification of its State of the Art MosaiQ™ Microarray Manufacturing Facility

JERSEY, Channel Islands, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported receipt of the formal ISO 13485:2016 certification for its state of the art MosaiQ™ multiplexing microarray manufacturing facility following the successful conclusion of the related European regulatory audit in September of this year....


Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

Novartis International AG / Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics...

Interim Durability Analysis of PTX-200 in Breast Cancer Responders Demonstrates No Disease Progression

Progression Free Survival  (PFS) and Overall Survival (OS) average 27 months Even partial responders remain free of disease progression Melbourne, Australia (10 December 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) today announced interim durability data on the PTX-200 study in HER2 negative locally advanced breast cancer. Follow-up s...

Thursday 6th December 2018

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The net proceeds to the Company from this offering are expected to be approximately $56.1 mi...

Wednesday 5th December 2018

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a ...

Tuesday 4th December 2018

Concept Life Sciences forms Scientific Advisory Board.

      SAB will help to guide Concept Life Sciences’ scientific strategy for its drug discovery and development services business SAB Members are leading experts in a diverse range of therapeutic areas   

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia

F. Hoffmann-La Roche Ltd / New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixe...

Monday 3rd December 2018

Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes

JERSEY, Channel Islands, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the indenture governing the Notes (the Indenture).    Franz Walt, Quotient’s Chief Executive Offi...

INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018

INNATE PHARMA ANNOUNCES UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2018 ANNUAL MEETING Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of lifeInnate Pharma expects to initiate a g...

Sunday 2nd December 2018

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS Microarray – Assay Performance Results of the V&V head-to-head study for the ...

Thursday 29th November 2018

Final Results for year ended 31 May 2018: Invoiced sales up 51% following significant contract, investment and restructuring

Cambridge, UK, 29 November 2018 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its full year results for the year to 31 May 2018. Operational highlights (including post period end) CE marked release of TexRAD® Lung in November 2017 Restructuring in April 2018 brought TexRAD Ltd and Cambridge...

Tuesday 27th November 2018

TwentyFour Select Monthly Income Fund - Issue of Equity

27 November 2018 TWENTYFOUR SELECT MONTHLY INCOME FUND LIMITED (a non-cellular company limited by shares incorporated in the Island of Guernsey under the Companies (Guernsey) Read more...

Wednesday 21st November 2018

Eckert & Ziegler BEBIG: Convening Notice of the Extraordinary General Meeting of Shareholders

CONVENING NOTICE OF THEEXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Eckert & Ziegler BEBIGLimited Liability Company offering its securities to the publicIndustrial Zone C, 7180 SeneffeVAT BE 457.288.682Register of Legal Entities Hainaut - Division Charleroiwww.bebig.com (the "Company")  The shareholders of the Company are invited to attend the extraordinary general ...

Tuesday 20th November 2018

Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies

                            PRESS RELEASE · PRESS RELEASE · PRESS RELEASE                  Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies Paris and Boston, November 20th 2018 - 17h45 CET (Euronext Growth Paris: ALNEV), leader in act...

Tuesday 13th November 2018

Veritas Announces Binding Share Purchase Agreement with Leis Industries Limited for Sale of Sechelt Organic Marijuana

VANCOUVER, British Columbia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a binding share purchase agreement (the “Agreement”) to sell 100% of the outstanding common shares of Sechelt Organic Marijuana Inc. (“Sechelt”) to Leis Industries Limited (“Le...

Kiadis Pharma to present at upcoming investor conferences in November 2018

    Kiadis Pharma to present at upcoming investor conferences in November 2018 Amsterdam, The Netherlands, November 13, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in Novembe...

Saturday 10th November 2018

Global Ear Anatomical Model Market Status and Outlook 20182025 [Report Updated: 19082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Friday 9th November 2018

Global Green Tea Essential Oil Extract Market Status and Outlook 20182025 [Report Updated: 19082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Thursday 8th November 2018

Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high bl...

Kiadis Pharma strengthens core team with three senior appointments

                           Amsterdam, The Netherlands, November 8, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has appointed three new senior team members to further strengthen the Company as it transitions into comm...

Wednesday 7th November 2018

Curetis raises €8.9 million through private placements

Curetis / Curetis raises €8.9 million through private placements . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE ...

Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma IL-4 / IL-13 Kinoid induces strong production of neutralizing antibodies against cytokines IL-4 and IL-13 and inhibits bronchoconstriction These results will help to define the future development i...

Esperite Group with The Cell Factory, expands its patent portfolio on extra-cellular vesicles biologic drugs in Canada.

Amsterdam, the Netherlands - 7 November 2018 Esperite's (Euronext: ESP) biotech company The Cell Factory has obtained the patent for the use of extracellular vesicles (EVs) in the treatment of acute and chronic inflammatory and autoimmune diseases in Canada. The Cell Factory has already protected IP for the EVs immunotherapeutic drugs use in Europe and China. The EVs paten...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks